EXTON, Pa., Feb. 27 /PRNewswire-FirstCall/ -- ViroPharma Incorporated
(Nasdaq: VPHM) reported today its financial results for the fourth quarter
and twelve months ended December 31, 2007.
Key events since September 30, 2007 include:
-- European Orphan Drug Designation received for Camvia(TM) (maribavir);
-- Patient enrollment continued in both phase 3 studies of Camvia in stem
cell and solid organ transplant patients;
-- Prelaunch activities for Camvia accelerated including new medical
affairs and PR initiatives in preparation for the planned 2009 NDA and
-- Monitoring and follow-up of patients who received HCV-796 in ongoing
phase 2 study continued; evaluation of potential benefits versus risks
to patients is ongoing to understand if and how further clinical
studies are appropriate; and
-- Work continued to optimize manufacturing and scale up for non-toxigenic
C. difficile (NTCD) project in preparation for human clinical trials.
-- Net sales of Vancocin(R) were $48 million;
-- Launched new sales and marketing initiatives for Vancocin; and
-- Research and development expenses increased by 305 percent over the
fourth quarter of 2006, primarily driven by investments in Camvia, NTCD
and increased personnel to support clinical momentum.
-- Operating income was $19 million;
-- Increased working capital by $21 million to $594 million;
-- Cash, cash equivalents and short-term investments grew by $32 million
to $584 million; and
-- 12th consecutive quarter of positive cash flow and profitability
|SOURCE ViroPharma Incorporated|
Copyright©2008 PR Newswire.
All rights reserved